Please take a moment to review the important CE information on this page.

Metastatic Breast Cancer: Individualizing Treatment
is no longer available for CME credit.

Accreditation

Physicians

The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

NCCN designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

This activity is approved for 1.0 contact hour. National Comprehensive Cancer Network is an approved provider of continuing nursing education by PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.

Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Contact NCCN at webcasts@nccn.org.

Program Overview
Metastatic breast cancer is breast cancer that has spread beyond the breast into places such as the bones, lungs, liver, or brain. Although metastatic breast cancer is not curable, there are many effective treatments, including a number of recent treatment advances, which are enabling women with metastatic breast cancer to live longer and better lives. However, treatment needs to be highly individualized and no single treatment plan is right for everyone.

Program Goal
The goal of this program is to provide participants with increased knowledge regarding the treatment of patients with metastatic breast cancer.

Learning Objectives
At the conclusion of this program, participants should be able to:

• Identify first-line and subsequent line endocrine therapy options for patients with hormone receptor positive cancer
• Identify treatment approaches for trastuzumab-exposed patients
• Describe single-agent and combination therapies, including biologic agents, being evaluated in clinical trials
• Counsel patients about some of the risks and benefits of therapeutic options
• Describe the appropriate use of supportive care options

Target Audience
Physicians, nurses, and other clinical professionals who manage patients with cancer.

Faculty Disclosure Information
All faculty participating in NCCN continuing education activities are expected to disclose any conflict(s) of interest related to the content of their presentation(s) as defined by the ACCME's and ANCC's Standards for Commercial Support.

Acknowledgement of Commercial Support
Supported by educational grants from AstraZeneca, Genentech, GlaxoSmithKline, and Pfizer.